| abstract |
Provided are novel treatment regimens involving the use of anti-IL-6 antibodies such as clazazizumab to prevent, stabilize, alleviate or arrest antibody-mediated rejection in patients receiving solid organ transplantation, such as those receiving a transplanted kidney , heart, liver, lung, pancreas, intestine, or a combination of any of the foregoing. In addition, there is provided a treatment involving the use of an anti-IL-6 antibody such as clazazizumab as part of a desensitization regimen for the treatment of highly sensitized subjects awaiting and/or following allograft transplantation Novel treatment regimens for, for example, patients who will receive a solid organ transplant such as kidney, heart, liver, lung, pancreas, intestine, skin, or a combination of any of the foregoing. The foregoing treatments may be performed in combination with one or more other immunosuppressive regimens or other desensitization procedures. |